Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma since June 2015. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010.
From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
What is Cooper C. Collins' net worth?
The estimated net worth of Cooper C. Collins is at least $69,486.90 as of August 21st, 2024. Mr. Collins owns 47,922 shares of TherapeuticsMD stock worth more than $69,487 as of November 15th. This net worth estimate does not reflect any other assets that Mr. Collins may own. Learn More about Cooper C. Collins' net worth.
How do I contact Cooper C. Collins?
Has Cooper C. Collins been buying or selling shares of TherapeuticsMD?
Cooper C. Collins has not been actively trading shares of TherapeuticsMD within the last three months. Most recently, on Wednesday, August 21st, Cooper C. Collins bought 1,200 shares of TherapeuticsMD stock. The stock was acquired at an average cost of $1.70 per share, with a total value of $2,040.00. Following the completion of the transaction, the director now directly owns 47,922 shares of the company's stock, valued at $81,467.40. Learn More on Cooper C. Collins' trading history.
Who are TherapeuticsMD's active insiders?
Are insiders buying or selling shares of TherapeuticsMD?
In the last twelve months, TherapeuticsMD insiders bought shares 1 times. They purchased a total of 1,200 shares worth more than $2,040.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 14,500 shares worth more than $33,495.00. The most recent insider tranaction occured on August, 21st when Director Cooper C Collins bought 1,200 shares worth more than $2,040.00. Insiders at TherapeuticsMD own 2.3% of the company.
Learn More about insider trades at TherapeuticsMD. Information on this page was last updated on 8/21/2024.
